Disease · MONDO_0021227
adrenal gland neoplasm
6 sourcesdiseases-2026-09-18-0.1.0
Cite this record
ConductScience Library. adrenal gland neoplasm. Diseases, record MONDO_0021227. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0021227
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Other names
ADRENAL GLAND NEOPL, Adrenal Cancer, Adrenal Cancers, Adrenal Gland Cancer, Adrenal Gland Cancers, Adrenal Gland Neoplasms, Cancer of the Adrenal Gland, Cancer, Adrenal, Cancer, Adrenal Gland, Cancers, Adrenal, Cancers, Adrenal Gland, NEOPL ADRENAL GLAND, Neoplasm, Adrenal, Neoplasm, Adrenal Gland, Neoplasms, Adrenal, Neoplasms, Adrenal Gland, adrenal gland neoplasm (disease), adrenal gland tumor, adrenal gland tumour, adrenal neoplasm, adrenal neoplasms, adrenal tumor, adrenal tumour, adrenal/paraganglial tumor, neoplasm of adrenal gland, neoplasm of the adrenal gland, tumor of adrenal gland, tumor of the adrenal gland, tumour of adrenal gland, tumour of the adrenal gland
- Open Targets
Drugs5
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| CISPLATIN | CHEMBL11359 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| CYCLOSPORINE | CHEMBL160 | Protein | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| DOXORUBICIN HYDROCHLORIDE | CHEMBL359744 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| METHOTREXATE | CHEMBL34259 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| TAMOXIFEN CITRATE | CHEMBL786 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
Targets4
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| DHFR | Dihydrofolate reductase | 1 | Dihydrofolate reductase inhibitor | Phase 2 | https://conductscience.org/library/genes/1719 | Drugs and targets |
| ESR1 | Estrogen receptor | 1 | Estrogen receptor alpha modulator | Phase 2 | https://conductscience.org/library/genes/2099 | Drugs and targets |
| PPIA | Peptidyl-prolyl cis-trans isomerase A | 1 | Cyclophilin A modulator | Phase 2 | https://conductscience.org/library/genes/5478 | Drugs and targets |
| TOP2A | DNA topoisomerase 2-alpha | 1 | DNA topoisomerase II alpha inhibitor | Phase 2 | https://conductscience.org/library/genes/7153 | Drugs and targets |
Trials2
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00001880 | Stem Cell Transplantation for Metastatic Solid Tumors | Phase 2 | 42 | 2021-11-10 | Neoplasm Metastasis | CYCLOSPORINE, METHOTREXATE | Its record names the disease | ClinicalTrials.gov |
| NCT00002608 | Combination Chemotherapy and Tamoxifen in Treating Patients With Solid Tumors | Phase 2 | 30 | Adrenocortical Carcinoma, Brain and Central Nervous System Tumors, Head and Neck Cancer, Liver Cancer, Malignant Mesothelioma, Pheochromocytoma, Sarcoma | CISPLATIN, DOXORUBICIN HYDROCHLORIDE, TAMOXIFEN CITRATE | Its record names the disease | ClinicalTrials.gov |
Comparisons in its trials0
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
None in this release.
Papers from its trials0
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
None in this release.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0021227
GET https://conductscience.org/api/diseases/v1/MONDO_0021227/drugs